Vascular Biogenics Ltd. (VBLT) Q1 2021 Earnings Conference Call May 11, 2021 8:30 AM ET
Company Participants
Lee Roth – Investor Relations
Dror Harats – Chief Executive Officer
Amos Ron – Chief Financial Officer
Conference Call Participants
Kevin DeGeeter – Oppenheimer
Arthur He – H.C. Wainwright
Lee Roth
Thank you, Sheryl. Good morning, and thank you joining today’s VBL Therapeutics First Quarter 2021 Financial Results and Corporate Update Conference Call. Leading the call this morning will be Prof. Dror Harats, Chief Executive Officer; and Amos Ron, Chief Financial Officer.
A press release with the company’s financial results was issued earlier this morning and as available on the Investor Relations page of the company’s website at vblrx.com.
Before I turn call over to management, I’d like to remind everyone that during this conference call forward-looking statements made by management are intended to fall within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, and Section 21E of the Securities Exchange Act of 1934, as amended. As set forth in our press release forward-looking statements, involve risks and uncertainties that may affect the company’s business and prospects, including those discussed in our filings with the SEC, which include among other things our Annual Report on Form 20-F. These filings are available from the SEC or on our website. Any forward looking statements made on today’s conference call speak only as of today’s date May 11, 2021, and the company does not intend to update any of these forward-looking statements to reflect events or circumstances that occur after today’s date.
As a reminder, the call is being recorded and will be available for audio rebroadcast on the company’s website. And we will have a Q&A session following today’s prepared remarks.
With that said, I’d now like to turn the call
- Read more current VBLT analysis and news
- View all earnings call transcripts